The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models-Reference-Cited by-同舟云学术

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Published:2018-10-16 Issue:81 Volume:9 Page:35226-35240
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Kim Sunkyu¹,Tiedt Ralph²,Loo Alice¹,Horn Thomas¹,Delach Scott¹,Kovats Steven¹,Haas Kristy¹,Engstler Barbara Schacher²,Cao Alexander¹,Pinzon-Ortiz Maria¹,Mulford Iain¹,Acker Michael G.¹,Chopra Rajiv³,Brain Christopher⁴,di Tomaso Emmanuelle¹,Sellers William R.¹,Caponigro Giordano¹

Affiliation:

1. Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA

2. Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland, USA

3. Novartis Institutes for BioMedical Research, Chemical Biology & Therapeutics, Cambridge, MA, USA

4. Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Cambridge, MA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic modeling of cell viability assays within silicolineage tracing;2024-08-26

2. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models;Clinical Cancer Research;2024-05-31

3. A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors;2024-04-25

4. Cardiovascular complications of ribociclib in breast cancer patients;Critical Reviews in Oncology/Hematology;2024-04

5. The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays;npj Breast Cancer;2024-03-04